Altamira Therapeutics

Name

Altamira Therapeutics

Legal name

Altamira Therapeutics AG

Website

https://altamiratherapeutics.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

siRNA Therapeutics (gene silencing) (HLAAADAB), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)

Keywords

• RNA delivery technology
• Peptide-based nanoparticles
• Nucleic acid therapeutics
• Allergic rhinitis treatment
• Inner ear therapeutics

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: Out-licensing of xPhore platform technology (OligoPhore, SemaPhore, CycloPhore, GenePhore) to pharma and biotech companies for their nucleic acid drug development programs.
2. Legacy Asset Divestiture: Partnering and divestiture of inner ear legacy assets including AM-125 (vertigo), AM-111/Sonsuvi (hearing loss), and AM-102 (tinnitus).
3. Associate Revenue (Altamira Medica): Altamira holds 49% stake in Altamira Medica AG which commercializes Bentrio nasal spray. Medica receives milestone payments from partners (e.g., $1M from Nuance Pharma for China approval) and generates commercial revenue through distribution partners.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Altamira Therapeutics is a holding company developing and commercializing nucleic acid delivery technologies and health products. Its core offering is the xPhore peptide-based nanoparticle platform (with variants OligoPhore, SemaPhore, CycloPhore, GenePhore) for extrahepatic delivery of siRNA, mRNA, circRNA, and DNA, out-licensed to pharma and biotech partners. It also commercializes Bentrio, a drug-free OTC nasal spray for allergic rhinitis, and develops inner ear/CNS therapeutics (AM-125, Sonsuvi/AM-111).

Product overview

Altamira Therapeutics is a biotech holding company developing nucleic acid delivery technologies and health products. The core offering is the xPhore peptide-based nanoparticle platform, which includes specialized delivery solutions: OligoPhore for siRNA, SemaPhore for linear mRNA, CycloPhore for circular RNA, and GenePhore for DNA. This platform enables delivery to extrahepatic tissues (beyond the liver) for pharma/biotech partners. The company also commercializes Bentrio, a drug-free OTC nasal spray for allergic rhinitis protection. Legacy assets include AM-125 (intranasal betahistine for vertigo, Phase 2), Sonsuvi/AM-111 (acute hearing loss treatment, Phase 3 with orphan status), AM-401 (KRAS cancer, preclinical), and AM-411 (rheumatoid arthritis, preclinical). The company operates through subsidiaries Altamira Therapeutics AG (nucleic acid delivery), Altamira Medica AG (Bentrio commercialization), and Otolanum AG (CNS therapeutics).

Differentiator

Problem solved

Functional benefit

Products and services

• xPhore Platform

Quantifiable outcome

• AM-125 showed 5-to-29 times higher bioavailability than oral betahistine in preclinical and clinical data
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Nuance PharmacoreChannel Partner/ Reseller/ Distributor · 19 December 2025Nuance Pharma is Altamira Medica's exclusive licensee and distribution partner for Bentrio nasal spray in Mainland China. Following NMPA approval in December 2025, Nuance will launch Bentrio in China where nearly 200 million people are estimated to suffer from allergic rhinitis. Altamira Medica received a $1 million milestone payment upon this approval.
• Circular RNA Delivery Partner (Undisclosed)strategicStrategic or Co-development Partner · 27 May 2025Collaboration to evaluate potential use of Altamira's proprietary CycloPhore platform for delivery of circular RNA payloads. Partner will have option to negotiate license agreement to develop and commercialize circRNA nanoparticles with their proprietary RNA payload upon successful evaluation.
• Radiopharmaceutical Sector Partner (Undisclosed)strategicStrategic or Co-development Partner · 22 January 2025Collaboration to evaluate use of Altamira's RNA delivery platform in conjunction with radiopharmaceutical cancer treatment. Testing in vitro and in vivo of nanoparticles with RNA payload combined with partner's proprietary radiopharmaceuticals. Partner has option to negotiate licensing and supply agreement upon successful conclusion.
• Univercells GroupstrategicTechnology or Integration · 1 August 2024Collaboration with Belgium-based Univercells Group to evaluate use of SemaPhore platform for delivery of mRNA vaccines. Lower mRNA loss during cell entrance may allow for using lower vaccine doses, potentially resulting in more effective and efficient vaccines.
• Altamira Therapeutics AGcoreOthersAltamira operates its nucleic acid delivery business through Swiss subsidiary Altamira Therapeutics AG (ATAG). The company is planning to spin off a majority of ATAG's share capital to private equity investors. ATAG raised $0.7M through convertible loans in 2025 ahead of planned 2026 equity funding round.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Alnylam Pharmaceuticals: Alnylam is the leading commercial siRNA company and has built the dominant GalNAc delivery platform for liver-targeted gene silencing. It is the most direct comparable to Altamira's ambition to deliver siRNA-based therapeutics via a differentiated delivery technology (OligoPhore/xPhore) and serves the same pharma/biotech partner ecosystem.
• Arcturus Therapeutics: Arcturus develops LNP-based delivery systems for mRNA and siRNA therapeutics, including extrahepatic applications. It directly competes with Altamira's xPhore strategy of offering non-LNP nucleic acid delivery to pharma partners and pursuing self-amplifying RNA platforms.
• Otonomy: Otonomy develops therapeutics for ear disorders, including hearing loss and tinnitus. It is a direct peer to Altamira's legacy inner ear programs (Sonsuvi/AM-111, AM-125, AM-102) and to its Otolanum AG subsidiary developing CNS therapeutics for neurological and inner ear indications.

Broad incumbents

• Acuitas Therapeutics: Acuitas is a leading LNP technology provider whose delivery IP underpins Moderna's COVID vaccine and several other RNA programs. Acuitas overlaps with Altamira as an enabling delivery partner for siRNA/mRNA developers but is much more entrenched in the LNP paradigm Altamira is trying to displace.
• Genevant Sciences: Genevant develops lipid nanoparticle and ligand-conjugated delivery systems for RNA therapeutics and is broadly comparable as a delivery-tech licensor targeting nucleic acid programs. It competes head-to-head with Altamira's xPhore platform for pharma/biotech licensing partnerships.
• Moderna: Moderna is a major commercial mRNA therapeutics company that uses LNP delivery at scale. It overlaps with Altamira's SemaPhore mRNA delivery ambitions and validates the market opportunity for novel RNA delivery systems, while representing the type of scaled player Altamira would aim to partner with or differentiate against.
• BioNTech: BioNTech develops mRNA-based vaccines and therapies with proprietary LNP delivery and an expanding pipeline across oncology and infectious disease. It is a broad incumbent comparable to Altamira on the mRNA delivery side and on the strategic importance of extrahepatic targeting, especially in immuno-oncology and protein replacement.

Emerging players

• Decibel Therapeutics: Decibel (acquired by Regeneron in 2024) was a clinical-stage biotech developing therapeutics for hearing loss and balance disorders. It serves as a relevant emerging-player comparable for Altamira's inner-ear therapeutic strategy, particularly around orphan-designated sudden sensorineural hearing loss treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/altamira-therapeutics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altamira Therapeutics